142 related articles for article (PubMed ID: 38073151)
1. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes.
Matsuo T; Wurster S; Jiang Y; Sasaki K; Tarrand J; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2024 Feb; 79(2):297-306. PubMed ID: 38073151
[TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis.
Fernández-Cruz A; Semiglia MA; Guinea J; Martínez-Jiménez MDC; Escribano P; Kwon M; Rodríguez-Macías G; Chamorro-de-Vega E; Rodríguez-González C; Navarro R; Galar A; Sánchez-Carrillo C; Díez-Martín JL; Muñoz P
Med Mycol; 2020 Apr; 58(3):300-309. PubMed ID: 31231772
[TBL] [Abstract][Full Text] [Related]
3. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Fanci R; Pini G; Bartolesi AM; Pecile P
Rev Iberoam Micol; 2013 Jan; 30(1):51-3. PubMed ID: 22659590
[TBL] [Abstract][Full Text] [Related]
4. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry.
Horn DL; Freifeld AG; Schuster MG; Azie NE; Franks B; Kauffman CA
Mycoses; 2014 Nov; 57(11):652-8. PubMed ID: 24943384
[TBL] [Abstract][Full Text] [Related]
5. Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015.
Pérez-Nadales E; Alastruey-Izquierdo A; Linares-Sicilia MJ; Soto-Debrán JC; Abdala E; García-Rodríguez J; Montejo M; Muñoz P; Lletí MS; Rezusta A; de Pipaón MRP; Yáñez L; Merino E; Campos-Herrero MI; Costa-Mateo JM; Fortún J; García-Lozano T; Garcia-Vidal C; Fernández-Ruiz M; Sánchez-Reus F; Castro-Méndez C; Guerrero-Lozano I; Soler-Palacín P; Aguado JM; Martínez-Martínez L; Torre-Cisneros J; Nucci M;
Emerg Infect Dis; 2021 Jan; 27(1):26-35. PubMed ID: 33352085
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of disseminated fusariosis with voriconazole in an acute lymphoblastic leukaemia patient.
Labois A; Gray C; Lepretre S
Mycoses; 2011 Dec; 54 Suppl 4():8-11. PubMed ID: 22126523
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
8. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Raad II; Hachem RY; Herbrecht R; Graybill JR; Hare R; Corcoran G; Kontoyiannis DP
Clin Infect Dis; 2006 May; 42(10):1398-403. PubMed ID: 16619151
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of invasive and non-invasive fusariosis in South Korea.
Park H; Bae S; Kim MJ; Chong YP; Kim SH; Choi SH; Lee SO; Kim YS; Jung J
Mycoses; 2023 Mar; 66(3):211-218. PubMed ID: 36349480
[TBL] [Abstract][Full Text] [Related]
12. Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia.
Gründahl M; Wacker B; Einsele H; Heinz WJ
Mycoses; 2020 Oct; 63(10):1101-1106. PubMed ID: 32738006
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis.
Ichikawa S; Fukuhara N; Watanabe S; Okitsu Y; Onodera K; Onishi Y; Harigae H
J Infect Chemother; 2020 Feb; 26(2):292-295. PubMed ID: 31570321
[TBL] [Abstract][Full Text] [Related]
15. Current antifungal treatment of fusariosis.
Al-Hatmi AMS; Bonifaz A; Ranque S; Sybren de Hoog G; Verweij PE; Meis JF
Int J Antimicrob Agents; 2018 Mar; 51(3):326-332. PubMed ID: 28705676
[TBL] [Abstract][Full Text] [Related]
16. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
[TBL] [Abstract][Full Text] [Related]
17. Improvement in the outcome of invasive fusariosis in the last decade.
Nucci M; Marr KA; Vehreschild MJ; de Souza CA; Velasco E; Cappellano P; Carlesse F; Queiroz-Telles F; Sheppard DC; Kindo A; Cesaro S; Hamerschlak N; Solza C; Heinz WJ; Schaller M; Atalla A; Arikan-Akdagli S; Bertz H; Galvão Castro C; Herbrecht R; Hoenigl M; Härter G; Hermansen NE; Josting A; Pagano L; Salles MJ; Mossad SB; Ogunc D; Pasqualotto AC; Araujo V; Troke PF; Lortholary O; Cornely OA; Anaissie E
Clin Microbiol Infect; 2014 Jun; 20(6):580-5. PubMed ID: 24118322
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
[TBL] [Abstract][Full Text] [Related]
19. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
Ping B; Zhu Y; Gao Y; Yue C; Wu B
Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
[TBL] [Abstract][Full Text] [Related]
20. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
